Suppression of store overload-induced calcium release by hydroxylated metabolites of carvedilol

详细信息    查看全文

• 作者：Thomas Malig^a ; Zhichao Xiao^b ; S.R. Wayne Chen^b ; ^{swchen@ucalgary.ca" class="auth_mail" title="E-mail the corresponding author} ; Thomas G. Back^a ; ^{tgback@ucalgary.ca" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Carvedilol metabolites ; Store overload-induced calcium release ; Ryanodine receptor ; HEK 293 mutant cell line (R4496C)
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2016
• 出版时间：1 January 2016
• 年：2016
• 卷：26
• 期：1
• 页码：149-153
• 全文大小：1099 K

文摘

Carvedilol is a drug widely used in the treatment of heart failure and associated cardiac arrhythmias. A unique action of carvedilol is its suppression of store overload-induced calcium release (SOICR) through the cardiac ryanodine receptor (RyR2), which can trigger ventricular arrhythmias. Since the effects of carvedilol metabolites on SOICR have not yet been investigated, three carvedilol metabolites hydroxylated at the 3-, 4′ and 5′-positions were synthesized and assayed for SOICR inhibition in mutant HEK 293 cells expressing the RyR2 mutant R4496C. This cell line is especially prone to SOICR and calcium release through the defective RyR2 channel was measured with a calcium-sensitive fluorescent dye. These results revealed that the 3- and 4′-hydroxy derivatives are slightly more effective than carvedilol in suppressing SOICR, while the 5′-analog proved slightly less active. Metabolic deactivation of carvedilol via these hydroxylation pathways is therefore insignificant.